The reporter learned recently from Pfizer that at the 5th International Fair, Pfizer will display nearly 20 breakthrough and innovative products and medical solutions, covering five major therapeutic fields: tumor, vaccine, anti infection, inflammation and immunity, and rare diseases. These include the highly anticipated combination packaging of COVID-19 therapeutic drug Nemartavir Tablets/Ritonavir Tablets (i.e. PAXLOVID), and the world's first CGRP receptor antagonist with rapidly dissolving orally disintegrating tablets (Rimegepant), which is also the only oral CGRP receptor antagonist approved in the world for both treatment and prevention of migraine. According to Peng Zhenke, president of Pfizer Global Biopharmaceutical Business Group in China, as of July 2022, there are 104 projects under research in Pfizer Global, "This is undoubtedly 104 potential opportunities to change the lives of patients in the world, including those in China. In fact, in 2022 alone, Pfizer will have up to 11 new products, new indications or new dosage forms approved in China. We are winning more hopes for patients at the rate of" new "every month." It is understood that since entering China for more than 30 years, Pfizer has introduced more than 60 innovative drugs to China, including original research drugs and vaccines. By 2025, Pfizer will also introduce 25 new products, new indications and new dosage forms to China to meet the health needs of patients throughout their life cycle. It is worth mentioning that while introducing innovative products, Pfizer also proposed the "two 80%" strategy: by the end of 2022, China will participate in more than 80% of global early and critical clinical research; 80% of the projects were declared at the same time and finally introduced into China. (Liu Xinshe)